company background image
ANR

Anatara LifesciencesASX:ANR Stock Report

Market Cap

AU$10.3m

7D

3.6%

1Y

-14.7%

Updated

26 Oct, 2021

Data

Company Financials
ANR fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ANR Overview

Anatara Lifesciences Limited engages in the research and development of evidence based solutions for gastrointestinal diseases in animals and humans in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Anatara Lifesciences
Historical stock prices
Current Share PriceAU$0.14
52 Week HighAU$0.14
52 Week LowAU$0.28
Beta1.06
1 Month Change-3.33%
3 Month Change-3.33%
1 Year Change-14.71%
3 Year Change-68.13%
5 Year Change-89.02%
Change since IPO-65.48%

Recent News & Updates

Shareholder Returns

ANRAU BiotechsAU Market
7D3.6%-0.09%0.8%
1Y-14.7%3.7%24.4%

Return vs Industry: ANR underperformed the Australian Biotechs industry which returned 3.7% over the past year.

Return vs Market: ANR underperformed the Australian Market which returned 24.4% over the past year.

Price Volatility

Is ANR's price volatile compared to industry and market?
ANR volatility
ANR Beta1.06
Industry Beta1.64
Market Beta1

Stable Share Price: ANR is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: ANR's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010n/aSteve Lydeamorehttps://www.anataralifesciences.com

Anatara Lifesciences Limited engages in the research and development of evidence based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming (GaRP), a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD); and 3FDC for the treatment of anxiety, stress, or depression. The company also provides Detach for the treatment of diarrhea disease in piglets.

Anatara Lifesciences Fundamentals Summary

How do Anatara Lifesciences's earnings and revenue compare to its market cap?
ANR fundamental statistics
Market CapAU$10.30m
Earnings (TTM)-AU$2.00m
Revenue (TTM)n/a

0x

P/S Ratio

-5.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ANR income statement (TTM)
RevenueAU$0
Cost of RevenueAU$840.82k
Gross Profit-AU$840.81k
ExpensesAU$1.16m
Earnings-AU$2.00m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.028
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ANR perform over the long term?

See historical performance and comparison

Valuation

Is Anatara Lifesciences undervalued compared to its fair value and its price relative to the market?

2.69x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ANR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ANR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ANR is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: ANR is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ANR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ANR is good value based on its PB Ratio (2.7x) compared to the AU Biotechs industry average (4.9x).


Future Growth

How is Anatara Lifesciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Anatara Lifesciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Anatara Lifesciences performed over the past 5 years?

-15.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ANR is currently unprofitable.

Growing Profit Margin: ANR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ANR is unprofitable, and losses have increased over the past 5 years at a rate of 15.9% per year.

Accelerating Growth: Unable to compare ANR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (48%).


Return on Equity

High ROE: ANR has a negative Return on Equity (-52.11%), as it is currently unprofitable.


Financial Health

How is Anatara Lifesciences's financial position?


Financial Position Analysis

Short Term Liabilities: ANR's short term assets (A$4.2M) exceed its short term liabilities (A$402.6K).

Long Term Liabilities: ANR's short term assets (A$4.2M) exceed its long term liabilities (A$94.1K).


Debt to Equity History and Analysis

Debt Level: ANR is debt free.

Reducing Debt: ANR has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ANR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ANR has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 9.1% each year.


Dividend

What is Anatara Lifesciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ANR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ANR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ANR's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Steve Lydeamore

2.83yrs

Tenure

AU$468,904

Compensation

Mr. Steven George Lydeamore, also known as Steve, MBA, CPA, serves as the Chief Executive Officer of Anatara Lifesciences Limited since December 2, 2018. Mr. Lydeamore served as the Chief Financial Officer...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD351.50K) is about average for companies of similar size in the Australian market ($USD301.38K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ANR's management team is seasoned and experienced (5.3 years average tenure).


Board Members

Experienced Board: ANR's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ANR insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.2%.


Top Shareholders

Company Information

Anatara Lifesciences Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Anatara Lifesciences Limited
  • Ticker: ANR
  • Exchange: ASX
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$10.298m
  • Shares outstanding: 71.02m
  • Website: https://www.anataralifesciences.com

Location

  • Anatara Lifesciences Limited
  • 62 Lygon Street
  • Level 3
  • Carlton
  • Victoria
  • 3053
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 07:01
End of Day Share Price2021/10/25 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.